C. Sidiropoulou

Early Start of Oral Clarithromycin Is Associated with Better Outcome in COVID-19 of Moderate Severity: The ACHIEVE Open-Label Single-Arm Trial

H. Milionis, E. Michelakis, E. Giamarellos‐Bourboulis, 2021, Infectious Diseases and Therapy.

Bloodstream Infections in a COVID-19 Non-ICU Department: Microbial Epidemiology, Resistance Profiles and Comparative Analysis of Risk Factors and Patients’ Outcome

A. Stamati, L. Velentza, O. Zarkotou, 2022, Microorganisms.

Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis

M. Netea, G. Chatellier, M. Sormani, 2021, The Lancet Rheumatology.

Early start of oral clarithromycin is associated with better outcome in COVID-19 of moderate severity: the ACHIEVE open-label trial

H. Milionis, E. Michelakis, E. Giamarellos‐Bourboulis, 2020 .

Oral clarithromycin in COVID-19 of moderate severity: the ACHIEVE open-label trial using concurrent matched comparators

K. Syrigos, H. Milionis, E. Michelakis, 2020, medRxiv.

Real life treatment experience and outcome of consecutively hospitalised patients with SARS-CoV-2 pneumonia by Omicron-1 vs Delta variants

N. Pantazis, A. Stamati, K. Zoi, 2023, Infectious diseases.